The FDA is alerting medical device users about a cybersecurity risk for the Medtronic MiniMed 600 Series Insulin Pump System (for example: MiniMed 630G and MiniMed 670G). There is a potential issue associated with the communication protocol for the pump system that could allow unauthorized access to the pump system. If unauthorized access occurs, the pump’s communication protocol could be compromised, which may cause the pump to deliver too much or too little insulin.
The MiniMed 600 series pump system has components that communicate wirelessly (such as the insulin pump, continuous glucose monitoring (CGM) transmitter, blood glucose meter, and CareLink USB device). For unauthorized access to occur, a nearby unauthorized person (person other than you or your care partner) would need to gain access to your pump while the pump is being paired with other system components.
The FDA is not aware of any reports related to this cybersecurity vulnerability.
Medtronic issued an
Urgent Medical Device CorrectionExternal Link Disclaimer to inform medical device users of this cybersecurity risk and included actions and recommendations for users to take.
The FDA is working with Medtronic to identify, communicate, and prevent adverse events related to this cybersecurity vulnerability. The FDA will keep the public informed if significant new information becomes available.
www.medtronicdiabetes.com
